Key Takeaways
- The federal government faces a shutdown by 12:01 a.m. Wednesday due to a stalled spending bill.
- The White House unveils TrumpRX for discounted medications; Pfizer commits to reduced drug rates.
- OpenAI launched a social media app for its AI video generator, competing with TikTok and YouTube.
- The $7,500 federal tax credit for new electric vehicles has expired, potentially impacting future sales.
- Major stock indexes saw gains; ExxonMobil announced 2,000 job cuts globally.
- Core Weave secured a $14.2 billion AI cloud infrastructure contract with Meta through 2031.
Deep Dive
- The federal government is likely to shut down at 12:01 a.m. Wednesday, as Congress failed to pass a stopgap spending bill.
- WSJ economics reporter Justin Lahart noted up to 800,000 workers could be furloughed, halting economic data collection.
- Disruptions are expected for government contractors, local businesses near federal facilities, and tourism at national parks.
- The shutdown is projected to reduce overall U.S. economic growth.
- Defense Secretary Pete Hagseth addressed military officers, focusing on strengthening physical fitness standards and criticizing diversity initiatives.
- President Trump discussed using the military to quell domestic disorder, alongside increased National Guard use in cities.
- A new national defense strategy emphasizes Western Hemisphere defense, including countering drug trafficking and deterring Venezuela in the Caribbean.
- The $7,500 federal tax credit for new electric vehicles has expired, potentially impacting future sales.
- Prior to expiration, August saw double-digit increases in EV sales as consumers sought the credit.
- John Murphy of Hague Partners stated EV penetration may drop significantly due to higher prices and "subpar products."
- Widespread EV adoption is projected to be years away following the credit's cessation.
- The White House unveiled TrumpRX, a direct-to-consumer website for Americans to buy medications at government-negotiated discounted prices.
- WSJ reporter Liz Essley Whyte noted Pfizer's commitment to offer some drugs at reduced rates, potentially linked to Most Favored Nation pricing.
- Pfizer received a three-year reprieve from national security-related 232 tariffs on non-U.S. manufactured products.
- This reprieve was granted in exchange for Pfizer's investments in domestic manufacturing facilities.